4.1 Article

Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole

Sara A. Scott et al.

Summary: This retrospective study aimed to compare the prophylactic efficacy of different antifungal drugs in preventing invasive fungal infections. The results showed that there was a similar incidence of fungal infections in patients who received isavuconazole prophylaxis compared to those who received posaconazole or voriconazole prophylaxis during acute myeloid leukemia treatment or post-hematopoietic cell transplantation.

TRANSPLANT INFECTIOUS DISEASE (2023)

Article Hematology

Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy

Koji Sasaki et al.

Summary: The progress in intensive chemotherapy and supportive care measures has improved survival in newly diagnosed AML patients. Risk classification based on factors such as age, frailty, organ dysfunction, cytogenetic abnormality, and infection can guide treatment intensity to avoid early mortality and improve survival rates.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Immunology

Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies

Caitlin R. Rausch et al.

Summary: The rate of breakthrough invasive fungal infections (bIFI) during remission induction chemotherapy was low (4%) in newly diagnosed AML patients receiving mold-active triazole antifungals for primary antifungal prophylaxis (PAP). Lower complete remission rate was observed in patients with bIFI. The rate of bIFI was comparable among different PAP agents and chemotherapy intensities.

CLINICAL INFECTIOUS DISEASES (2022)

Article Immunology

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Prithviraj Bose et al.

Summary: In patients with newly diagnosed AML/MDS undergoing remission-induction chemotherapy, ISAV is a safe and effective alternative for antifungal prophylaxis, with excellent tolerability and minimal adverse effects such as mild to moderate elevation of liver function tests.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience

Christine A. Vu et al.

Summary: The study evaluated the efficacy of isavuconazole in treating invasive fungal disease and found it to be a promising alternative with high efficacy and safety. The breakthrough rate for invasive fungal disease was 8.5% in patients and 7.8% in courses.

TRANSPLANT INFECTIOUS DISEASE (2021)

Article Oncology

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach

Sumit Bhatnagar et al.

Summary: The study developed and clinically verified posaconazole PBPK models, and predicted the exposures of venetoclax when co-administered with delayed release tablets of posaconazole. The results showed that the exposures were within the safe range, confirming the venetoclax label recommendation in the presence of posaconazole at doses up to 500 mg QD.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Hematology

Venetoclax-based therapies for acute myeloid leukemia

Veronica A. Guerra et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)

Article Microbiology

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

David Andes et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Infectious Diseases

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Francisco M. Marty et al.

LANCET INFECTIOUS DISEASES (2016)

Article Medicine, General & Internal

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Oliver A. Cornely et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

Andrew J. Ullmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)